Thus, treatments that combine EGFR inhibitors with conventional chemotherapy will target both the bulk of the tumor and the cancer stem cell subpopulation, greatly reducing the possibility of relapse and secondary tumors. This evidence concerns the gene EGFR and neoplasm.